Global Peritoneal Dialysis Market Report and Forecast 2025-2034

Global Peritoneal Dialysis Market Outlook

The global peritoneal dialysis market size attained a value of nearly USD 4,932.07 million in 2024. The market is likely to grow at a CAGR of 6.4% during the forecast period of 2025-2034 to attain a value of USD 8,619.93 million by 2034.

Key Trends in the Market

With peritoneal dialysis (PD), a soft plastic tube or catheter is surgically implanted into the abdominal lining or belly to treat kidney failure. The two types of peritoneal dialysis are continuous ambulatory peritoneal dialysis (CAPD) and continuous cycling peritoneal dialysis (CCPD). These methods enable more flexible treatment options, lessen the need to visit dialysis facilities, and produce better clinical results, which means less drugs and fewer dietary restrictions.

• Peritoneal dialysis has the benefit that it can be performed at home and does not necessitate frequent journeys to a dialysis facility. Patients undergoing peritoneal dialysis also have less food and fluid restrictions than those undergoing haemodialysis. This is anticipated to increase the demand for peritoneal dialysis and, as a result, fuel the peritoneal dialysis market growth in the upcoming years.

• The rising incidence of diabetes, hypertension, and end-stage renal disease (ESRD), along with the growing need for kidney donors and the growing consumer knowledge of the hazards of kidney transplants, are the primary factors driving the market's expansion.

• The significant increase in chronic kidney disease (CKD) in recent years can be linked to the increasing prevalence of high blood pressure and diabetes. Over time, CKD is worsening and raising the risk of developing heart disease and stroke. This has increased the peritoneal dialysis demand, which is significantly boosting peritoneal dialysis market development.

• The market is further expanding due to a shift in health professionals' preferences for PD over haemodialysis, which offers better patient mobility at affordable costs while producing less symptom variations. Along with this, various government spending on research and development (R&D), improving reimbursement practises, and ongoing product diversification are encouraging the market expansion.

Global Peritoneal Dialysis Market Analysis

Based on treatment type, the market is segmented into continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD). The market on the basis of product can be divided into peritoneal dialysis solution, peritoneal dialysis devices, peritoneal dialysis sets, and peritoneal dialysis catheters, among others. On the basis of end use, the market is divided into home-based dialysis and dialysis centre and hospital-based dialysis. The regional markets for peritoneal dialysis can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global peritoneal dialysis market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.  

• Baxter International, Inc.

• B. Braun Melsungen AG

• Fresenius Medical Care AG & Co. KGaA 

• Medtronic plc 

• Medionics International Inc. 

• Newsol Technologies Inc. 

• Others

Market Share by Treatment Type

The continuous ambulatory peritoneal dialysis (CAPD) market is anticipated to have significant revenue growth during the forecast period. CAPD is a type of peritoneal dialysis that can be done manually, without a machine, and constantly throughout the day. The method is new for the treatment of end-stage renal disease. The benefits include improved blood pressure management, a discernible improvement in anaemia, and an unrestricted diet, thus aiding the peritoneal dialysis market growth. 

Additionally, CAPD provides a greater clearance of medicines with a higher molecular weight than haemodialysis. Both therapies are intended to be performed over a 24-hour period, however CAPD does not employ a cycler and APD does. The cycler is a programmable machine that controls the solution exchange, enabling usage of APDs throughout the night while the patient is asleep. 

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Market Share by Region

North America is anticipated to hold one of the largest market shares during the forecast period. This is due to the high awareness of the peritoneal dialysis technology, the established healthcare industry, and the rising incidence of end-stage renal disease (ESRD) and chronic kidney disease (CKD). 

An increase in CKD patients in North America has been caused by the rising numbers of people with diabetes and high blood pressure. This has caused a sharp increase in the demand for peritoneal dialysis among kidney patients, which is anticipated to propel the peritoneal dialysis market in the region. Additionally, the existence of significant producers like Baxter, and other leading producers has improved access to a variety of dialysis products at competitive prices, which is anticipated to fuel the regional market growth. 

Competitive Landscape

Baxter International, Inc., which was established in 1931 and has its headquarters in the United States, offers a variety of medical supplies. Its product and service offerings include sterile intravenous solutions, generic injectable medications, parenteral nutrition therapy, infusion systems and devices, inhaled anaesthetics, surgical haemostat and sealant products, and dialysis for both acute and chronic illnesses.

B. Braun Melsungen AG, since its founding in 1839 has developed, produced, and distributed pharmaceutical and medical technology goods as well as offered healthcare services. B. Braun sells equipment and systems for surgery, extracorporeal blood transfusion, intensive care, and anaesthesia. Additionally, it provides services for medical practises, clinics, and the home health care industry. 

Fresenius Medical Care AG & Co. KGaA, a global healthcare company with its headquarters in Germany and founded in 1996, provides high-quality goods and services for hospitals, outpatient care, and dialysis, with about 3.8 million patients receiving dialysis on a regular basis globally. 

Other market players include Medtronic plc, Medionics International Inc., and Newsol Technologies Inc., among others.

Key Highlights of the Report